Mankind Pharma Quarterly Results for Trading Insights
In Mar 2026, Mankind Pharma (MANKIND) reported revenue ₹3,560 Cr and net profit ₹559 Cr — revenue +6.8% YoY. Analyse MANKIND shareholding pattern to track promoter, FII and institutional holdings.
MANKIND Quarterly Results — Revenue, Profit & EPS Highlights
Mankind Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit MANKIND share price.
- Revenue of ₹3,560 Cr in Mar 2026 (-12.7% vs Jun 2026, +6.8% vs Mar 2025)
- Net Profit of ₹559 Cr in Mar 2026 (-2.6% vs Jun 2026, +31.5% vs Mar 2025)
- EBITDA of ₹1,024 Cr in Mar 2026 (-7.3% vs Jun 2026)
- Operating Margin of 26.0% in Mar 2026 (+0.0pp vs Jun 2026)
- Earnings Per Share of ₹13.44 in Mar 2026 (-2.3% vs Jun 2026)
Mankind Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
MANKIND quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 3,560 | 4,080 | 3,791 | 3,333 | 3,653 | -12.7% | 6.8% |
| Net Profit (₹ Cr) | 559 | 574 | 520 | 425 | 445 | - | - |
| EBITDA (₹ Cr) | 1,024 | 1,105 | 1,016 | 933 | 930 | - | - |
| EPS (₹) | 13.44 | 13.76 | 12.39 | 10.19 | 10.62 | - | - |
| Operating Margin (%) | 26.0% | 26.0% | 25.0% | 22.0% | 24.0% | - | - |
MANKIND Share Price Trend — 1-Year Movement Across Quarterly Results
Mankind Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View MANKIND 52-week performance for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
MANKIND vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Mankind Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,477.63 Cr | 1837.3 | 15,018 | 2,710 | -5.6% | - | 18.0% | 162.6 |
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Cipla
Mar 2026 |
₹112,654.03 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
All amounts in ₹ Crores